NDAORALTABLET, FOR SUSPENSIONPriority Review
Approved
Jun 2020
Lifecycle
Peak
Competitive Pressure
8/100
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
TIVICAY PD is an oral, fixed-dose combination tablet containing dolutegravir, abacavir, and lamivudine for the treatment of HIV-1 infection. It is an integrase strand transfer inhibitor (INSTI)-based regimen that works by blocking HIV replication at the integration step. The PD formulation (pediatric dispersible) enables dosing flexibility for patients with swallowing difficulties or those requiring dose adjustments.
$0.036BPart D
Peak4.1 years to LOETIVICAY PD is in peak commercial phase with modest Part D penetration, suggesting a mid-sized brand team focused on market consolidation rather than rapid expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Why This Matters for Your Career
LOE in ~5 years — strategic planning for patent cliff underway
Worked on TIVICAY PD at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.